serplulimab + nab-paclitaxel + epirubicin

Serplulimab + nab-paclitaxel + epirubicin is a combination regimen under investigation for the treatment of early-stage hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. The regimen combines: - **Serplulimab**, a novel humanized monoclonal antibody targeting programmed death-1 (PD-1), which acts as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses. - **Nab-paclitaxel** (nanoparticle albumin-bound paclitaxel), a microtubule inhibitor chemotherapeutic agent that disrupts cell division. - **Epirubicin**, an anthracycline chemotherapeutic that intercalates DNA and inhibits topoisomerase II, leading to cytotoxicity in rapidly dividing cells. This combination is being studied as neoadjuvant therapy, aiming to improve pathological complete response rates prior to surgery in patients with early-stage HR+/HER2- breast cancer[4][10]. Serplulimab has also been investigated in other cancers such as cervical cancer and non-small cell lung cancer when combined with nab-paclitaxel[1][6][7].

Brand names

HanzaizeAbraxaneEllence

Other names

serplulimab + NabPEserplulimab plus neoadjuvant nab-PEserplulimab + albumin-bound paclitaxel + epirubicin